# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...
Raymond James analyst Steven Seedhouse reiterates Viking Therapeutics (NASDAQ:VKTX) with a Strong Buy.
Maxim Group analyst Naz Rahman reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $120 price target.
Viking Therapeutics reports promising 52-week data from its Phase 2b VOYAGE study on VK2809 for NASH.